Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malign...
Hlavní autoři: | Grandclément, C, Estoppey, C, Dheilly, E, Panagopoulou, M, Monney, T, Dreyfus, C, Loyau, J, Labanca, V, Drake, A, De Angelis, S, Rubod, A, Frei, J, Caro, LN, Blein, S, Martini, E, Chimen, M, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoelen, C, Pellat-Deceunynck, C, Moreau, P, Mbow, ML, Srivastava, A, Dyson, MR, Zhukovsky, EA, Perro, M, Sammicheli, S |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Springer Nature
2024
|
Podobné jednotky
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Autor: C. Grandclément, a další
Vydáno: (2024-03-01) -
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
Autor: Jeremy Loyau, a další
Vydáno: (2025-12-01) -
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
Autor: C. Grandclement, a další
Vydáno: (2022-06-01) -
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Autor: Pouleau, B, a další
Vydáno: (2023) -
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Autor: Carretero-Iglesia, L, a další
Vydáno: (2024)